Incyclinide

Incyclinide (proposed trade name Metastat) is a chemically modified tetracycline antibiotic that was investigated in clinical trials for the treatment of rosacea,[1] various tumours, allergic and inflammatory diseases and a number of other conditions.[2][3] The drug lacks antibiotic properties but retains or enhances the inhibition of metalloproteinase.[4]

Incyclinide
Clinical data
Trade namesMetastat (proposed)
ATC code
  • none
Legal status
Legal status
  • Abandoned?
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC19H17NO7
Molar mass371.345 g·mol−1
3D model (JSmol)

Mechanism of action

Like other tetracyclines, incyclinide inhibits matrix metalloproteinases.[4]

References

  1. Reuters: CollaGenex says incyclinide ineffective for rosacea
  2. H. Spreitzer (2 July 2007). "Neue Wirkstoffe - Incyclinid". Österreichische Apothekerzeitung (in German) (14/2007): 655.
  3. ClinicalTrials.gov: Incyclinide
  4. Viera, MH, Perez, OA, Berman, B. "Incyclinide". Drugs of the Future. 32 (3): 209–214. doi:10.1358/dof.2007.032.03.1083308.CS1 maint: multiple names: authors list (link)


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.